Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD)

Oncogene

Volumn 32, Issue 7, 2013, Pages 827-836

  Campbell, H G ^a   Mehta, R ^a   Neumann, A A ^a   Rubio, C ^a   Baird, M ^b   Slatter, T L ^c   Braithwaite, A W ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

apoptosis; DNA repair; p53

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FIBROBLAST; GAMMA RADIATION; HYPEROXIA; IN VIVO STUDY; IONIZING RADIATION; LIVER; LUNG; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROLINE RICH PROTEIN DOMAIN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA DAMAGE; EMBRYO, MAMMALIAN; EMBRYONIC STEM CELLS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PROLINE; PROLINE-RICH PROTEIN DOMAINS; RADIATION, IONIZING; SEQUENCE DELETION; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84874108839     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.102     Document Type: Article

References (37)

1. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 Mutations in Human Cancers. Science 1991; 253: 49-53.
3. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
4. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
5. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
6. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
7. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor Spectrum Analysis in P53-Mutant Mice. Curr Biol 1994; 4: 1-7.
8. Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery CA, Butel JS et al. Mice Deficient for P53 Are Developmentally Normal But Susceptible to Spontaneous Tumors. Nature 1992; 356: 215-221.
9. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
10. Braithwaite AW, Royds JA, Jackson P. The p53 story: layers of complexity. Carcinogenesis 2005; 26: 1161-1169.
11. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
12. Walker K, Levine A. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci 1996; 93: 15335-15340.
13. Baptiste N, Friedlander P, Chen XB, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 2002; 21: 9-21.
14. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998; 17: 4668-4679.
15. Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW. The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 2003; 22: 4517-4523.
16. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer cell 2006; 9: 273-285.
17. Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G et al. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Differ 2010; 17: 540-550.
18. Teodoro JG, Shore GC, Branton PE. Adenovirus E1A Proteins Induce Apoptosis by Both P53-Dependent and P53-Independent Mechanisms. Oncogene 1995; 11: 467-474.
19. Hansen RS, Braithwaite AW. The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras. Oncogene 1996; 13: 995-1007.
20. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988; 334: 124-129.
21. Braithwaite AW, Cheetham BF, Li P, Parish CR, Waldronstevens LK, Bellett AJD. Adenovirus-Induced Alterations of the Cell-Growth Cycle-A Requirement for Expression of E1A But Not of E1B. J Virol 1983; 45: 192-199.
22. Lowe SW, Ruley HE. Stabilization of the P53 Tumor Suppressor Is Induced by Adenovirus-5 E1A and Accompanies Apoptosis. Gene Dev 1993; 7: 535-545.
23. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003; 5: 741-747.
24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868.
26. Horn PL, Turker MS, Ogburn CE, Disteche CM, Martin GM. A Cloning Assay for 6-Thioguanine Resistance Provides Evidence Against Certain Somatic Mutational Theories of Aging. J Cell Physiol 1984; 121: 309-315.
27. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997; 15: 887-898.
28. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol 2007; 27: 1425-1432.
29. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002; 22: 1834-1843.
30. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A et al. Integration of TGF-+f and Ras/MAPK Signaling Through p53 Phosphorylation. Science 2007; 315: 840-843.
31. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20: 398-400.
32. Lee JH, Paull TT. Direct Activation of the ATM Protein Kinase by the Mre11/Rad50/Nbs1 Complex. Science 2004; 304: 93-96.
33. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P. Mice Lacking P21(C/P1/Waf1) Undergo Normal Development, But Are Defective in G1 Checkpoint Control. Cell 1995; 82: 675-684.
34. Michalak EM, Villunger A, Adams JM, Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 2008; 15: 1019-1029.
35. Salvador JM, Hollander MC, Nguyen AT, Kopp JB, Barisoni L, Moore JK et al. Mice lacking the p53-effector gene Gadd45a develop a Lupus-like syndrome. Immunity 2002; 16: 499-508.
36. Xu J. Preparation, Culture, and Immortalization of Mouse Embryonic Fibroblasts. John Wiley & Sons Inc., New York, NY, USA, 2001.
37. Samuelson AV, Lowe SW. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci USA 1997; 94: 12094-12099.